SIC
RPRX icon

SJS Investment Consulting’s Royalty Pharma RPRX Stock Holding History

SJS Investment Consulting’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.9K Buy
409
+92
+29% +$4.79K ﹤0.01% 745
2026
Q1 		$15.2K Buy
317
+211
+199% +$9.24K ﹤0.01% 730
2025
Q4 		$4.1K Sell
106
-419
-80% -$16K ﹤0.01% 987
2025
Q3 		$18.5K Buy
525
+419
+395% +$15.2K ﹤0.01% 539
2025
Q2 		$3.82K Hold
106
– – ﹤0.01% 437
2025
Q1 		$3.3K Hold
106
– – ﹤0.01% 557
2024
Q4 		$2.71K Hold
106
– – ﹤0.01% 593
2024
Q3 		$3K Hold
106
– – ﹤0.01% 626
2024
Q2 		$2.8K Hold
106
– – ﹤0.01% 589
2024
Q1 		$3.22K Buy
+106
New +$3.13K ﹤0.01% 571

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SJS Investment Consulting's RPRX Position: Q2 2026 in Review

SJS Investment Consulting increased its Royalty Pharma (RPRX) stake by 29% in Q2 2026, buying an estimated $4.79K and bringing the position to 409 shares worth $22.9K. The position accounts for ﹤0.01% of the portfolio, ranked #745.

SJS Investment Consulting first reported a position in RPRX in Q1 2024 and has held it in 10 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • SJS Investment Consulting held 409 shares of Royalty Pharma worth $22.9K as of Q2 2026.
  • SJS Investment Consulting bought 92 Royalty Pharma shares in Q2 2026, an estimated $4.79K.
  • Royalty Pharma made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #745 holding.
  • SJS Investment Consulting first reported a position in Royalty Pharma in Q1 2024 and has held it in 10 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.